Core Viewpoint - Jiangsu Hualan Pharmaceutical Materials Co., Ltd. plans to utilize idle funds for cash management, aiming to enhance the efficiency of fund usage while ensuring that it does not affect the construction of fundraising investment projects and the company's normal operations [1][2]. Fund Scale and Investment Scope - The company intends to use up to 1.1 billion yuan for cash management over the next 12 months, with a cap of 800 million yuan from idle fundraising and 300 million yuan from self-owned funds. The funds will be invested in low-risk, liquid principal-protected products such as structured deposits and time deposits, with a maximum investment period of 12 months [1][2]. Historical Review of Fund Usage - Hualan Co. raised a net amount of 1.804 billion yuan during its IPO in 2021, with initial plans to invest 550 million yuan in automation upgrades and working capital. The company has since expanded its capacity through additional fundraising, including 300 million yuan for pre-filled packaging materials and 576 million yuan for a subsidiary project [3]. Changes in Cash Management Scale - The company has gradually adjusted its cash management strategy, reducing the scale from 1.55 billion yuan in December 2023 to 1.3 billion yuan in November 2024, and now to 1.1 billion yuan in the current plan [4]. Risk Control and Opinions - A multi-level control mechanism has been established to mitigate investment risks, including decision-making authority granted to the chairman, implementation by the finance department, and regular audits by the audit department. The independent directors and the sponsor institution have confirmed that the cash management plan complies with regulatory requirements and does not alter the use of fundraising [4].
华兰股份拟动用11亿元闲置资金进行现金管理 含8亿元募集资金